Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC administrators

This article was originally published in The Tan Sheet

Executive Summary

Deborah Majoras "is a highly talented and experienced lawyer, and will be an excellent chairman" of the Federal Trade Commission, Timothy Muris says of his successor in a recent statement. Muris' resignation as FTC chairman takes effect Aug. 15; Majoras' nomination was announced in May (1"The Tan Sheet" May 17, 2004, p. 14)...

You may also be interested in...



FTC appointment

Jon Leibowitz has been sworn in as one of five Federal Trade commissioners, replacing Mozelle Thompson, a commissioner since 1996. Leibowitz was Democratic chief counsel and staff director to the Senate Antitrust Subcommittee from 1997 to 2000, and chief counsel to Senator Herb Kohl (D-Wisc.) from 1989 to 2000. Most recently Leibowitz was vice president of congressional affairs for the Motion Picture Association of America. His appointment follows shortly after Deborah Majoras replaced Timothy Muris as chairman (1"The Tan Sheet" Aug. 16, 2004, In Brief)...

FTC Chairman Nominee Majoras Represented Aventis In Price-Fixing Case

FTC chairman nominee Deborah Majoras offers an extensive background in antitrust litigation, including work on vitamin price-fixing, to her new role at the agency

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel